News

May 12, 2026

Mabwell to Present Two Clinical Study Results as Oral Presentation at Retina China 2026

➞

May 08, 2026

World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application

➞

Apr 30, 2026

2026 WOC | Mabwell to Present Latest Clinical Data on 9MW0211 for nAMD in Poster Presentations

➞

Apr 29, 2026

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

➞

Apr 28, 2026

Mabwell Lists on HKEX and Joins Stock Connect, Entering New Phase of Internationalization

➞

Apr 23, 2026

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

➞

Apr 23, 2026

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

➞

Apr 22, 2026

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

➞

Apr 21, 2026

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

➞

Apr 16, 2026

Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market

➞